Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: The CHROME study

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1255-1268

  Lam, Wai Ching ^a   Albiani, David A ^b   Yoganathan, Pradeepa ^c   Chen, John Chanchiang ^d   Kherani, Amin ^e   Maberley, David A L ^f   Oliver, Alejandro ^g   Rabinovitch, Theodore ^c   Sheidow, Thomas G ^h   Tourville, Eric ⁱ   Wittenberg, Leah A ^j   Sigouin, Chris ^k   Baptiste, Darryl C ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b West Coast Retinal Consultants   (Canada)

^c North Toronto Eye Care   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e Department of Pediatrics   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Timmins and District Hospital   (Canada)

^h Ivey Eye Institute   (Canada)

ⁱ Inst Microchir Oculaire de Quebec   (Canada)

^j Retina Surgical Associates   (Canada)

^k Clinwest Research Inc   (Canada)

^l ALLERGAN PLC   (United States)

more..

Author keywords

Diabetic macular edema; Ozurdex ; Posterior segment inflammatory disease; Registry; Retinal vein occlusion; Sustained release dexamethasone implant

Indexed keywords

DEXAMETHASONE;

AGED; ARTICLE; CATARACT EXTRACTION; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RETINA DETACHMENT; RETINA VEIN OCCLUSION; RETINAL THICKNESS; RETROSPECTIVE STUDY; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; UVEITIS; VERY ELDERLY; VISUAL ACUITY;

EID: 84937709345     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S80500     Document Type: Article

References (29)

1. Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal vascular disease. Ophthalmologica. 2010;224 Suppl 1:16–24.
2. Wolfensberger TJ, Gregor ZJ. Macular edema – rationale for therapy. Dev Ophthalmol. 2010;47:49–58.
3. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treat­ment of retinal diseases. Scientific World Journal. 2014;2014:989501.
4. Hardman JG, Limburd LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman’s: The Pharmacological Basis of Thera­peutics. 9th ed. New York, NY , USA: McGraw-Hill; 1996.
5. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259–266.
6. Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravit­real dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology. 1991;98:1370–1375.
7. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol. 1991;15:233–235.
8. Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Package insert]. Irvine, CA, USA. Allergan, Inc.; 2014.
9. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29:46–51.
10. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.
11. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317.
12. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.
13. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central reti­nal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–2460.
14. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Oph­thalmol. 2011;129:545–553.
15. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915–923.
16. Shaikh AH, Petersen MR, Sisk RA, Foster RE, Riemann CD, Miller DM. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema second­ary to central retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2013;44:28–33.
17. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914.
18. Bezatis A, Spital G, Hohn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – the SOLO study. Acta Ophthalmol. 2013;91: e340–e347.
19. Capone A Jr, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study). Retina. 2014;34:342–351.
20. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina. 2013;33:1227–1231.
21. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231:141–146.
22. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthal­mologica. 2012;228:117–122.
23. Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121:1649–1654.
24. Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Product mono­graph]. Markham, ON, Canada; Allergan Inc.; 2015.
25. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388–391.
26. Zalewski D, Raczynska D, Raczynska K. Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant. Mediators Inflamm. 2014;2014:364143.
27. Petrash JM. Aging and age-related diseases of the ocular lens and vitre­ous body. Invest Ophthalmol Vis Sci. 2013;54:ORSF54–ORSF59.
28. Bhatnagar P, Schiff WM, Barile GR. Diabetic vitrectomy: the influence of lens status upon surgical outcomes. Curr Opin Ophthalmol. 2008; 19:243–247.
29. Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol. 2012;51:29–46.